Ab­b­Vie is gun­ning for ac­cel­er­at­ed ap­proval of an­ti­body-drug con­ju­gate af­ter pos­i­tive PhII da­ta

Ab­b­Vie plans to ex­plore ac­cel­er­at­ed ap­proval for its an­ti­body-drug con­ju­gate as a monother­a­py in non-small cell lung can­cer fol­low­ing pos­i­tive Phase II topline da­ta.

Teliso­tuzum­ab-ve­dotin, al­so called Teliso-V, is be­ing in­ves­ti­gat­ed in pa­tients with c-Met pro­tein over-ex­pres­sion, epi­der­mal growth fac­tor re­cep­tor (EGFR) wild type, ad­vanced or metasta­t­ic non­squa­mous non-small cell lung can­cer (NSCLC). C-Met is a re­cep­tor ty­ro­sine ki­nase that is over-ex­pressed in many sol­id tu­mors, in­clud­ing NSCLC. The Phase II LU­MI­NOS­I­TY tri­al used the drug as a sec­ond- or third-line treat­ment for pa­tients whose can­cer over-ex­pressed c-Met.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER